Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Research Antibodies Market Size Worth $5.9 Billion By 2028 | CAGR: 6.4%: Grand View Research, Inc.

This image opens in the lightbox

News provided by

Grand View Research, Inc.

02 Sep, 2021, 09:05 GMT

Share this article

Share toX

Share this article

Share toX

SAN FRANCISCO, Sept. 2, 2021 /PRNewswire/ -- The global research antibodies market size is expected to reach USD 5.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.4% from 2021 to 2028. Major market drivers include a rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, an increase in neurobiology and stem cell research, availability of technologically advanced products, and strategic collaborations among various key players.

Key Insights & Findings:

  • In 2020, primary antibodies held a dominant share in terms of revenue in the product segment owing to greater specificity, therefore, leading to increase adoption in R&D activities
  • Monoclonal antibodies captured a substantial share in 2020, as they offer higher sensitivity for the detection of antigens and also showcase efficient staining properties for various applications
  • The neurobiology segment is expected to witness exponential growth over the forecast period owing to the increasing prevalence of diseases that have limited treatment options and the rise in R&D activities by biotech companies and academic institutes
  • Pharmaceutical and biotechnology companies were dominant in terms of revenue amongst all end-users in 2020, owing to the increased adoption of research antibodies in drug development and discovery
  • In 2020, North America accounted for the substantial revenue share which is attributable to the high presence of many biotechnologies as well as biopharmaceutical manufacturers, research academies, and laboratories

Read 140 page market research report, "Research Antibodies Market Size, Share & Trends Analysis Report By Product (Primary, Secondary), By Type (Monoclonal Antibodies, Polyclonal Antibodies), By Technology, By Source, By Application, By End-use, By Region, And Segment Forecasts, 2021 - 2028", by Grand View Research

An increase in the usage of research antibodies to develop therapies for various chronic and infectious diseases, including COVID-19, is anticipated to boost the market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid scientists in understanding various aspects of virus pathogenesis entailing further research on antiviral therapies. Growing government funds and initiatives for R&D are anticipated to fuel market growth during the forecast period in the Asia Pacific region. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, a rise in funds invested by pharmaceutical and biotechnology companies to enhance proteomics and genomics research is expected to boost market growth. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. The rise in the number of major players investing in advanced technologies and collaborating with other key players is also anticipated to impact market potential positively in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies. Moreover, the launch of novel antibody structures for the diagnosis of various diseases is also a major factor expected to boost market growth. For instance, in August 2018, BioGenex launched a range of new antibodies for its use in cancer immunohistochemistry.

Grand View Research has segmented the global research antibodies market on the basis of product, type, technology, source, application, end-use, and region:

  • Research Antibodies Product Outlook (Revenue, USD Million, 2018 - 2028)
    • Primary
    • Secondary
  • Research Antibodies Type Outlook (Revenue, USD Million, 2018 - 2028)
    • Monoclonal Antibodies
    • Polyclonal Antibodies
  • Research Antibodies Technology Outlook (Revenue, USD Million, 2018 - 2028)
    • Immunohistochemistry
    • Immunofluorescence
    • Western Blotting
    • Flow Cytometry
    • Immunoprecipitation
    • ELISA
    • Other Technologies
  • Research Antibodies Source Outlook (Revenue, USD Million, 2018 - 2028)
    • Mouse
    • Rabbit
    • Goat
    • Other Sources
  • Research Antibodies Application Outlook (Revenue, USD Million, 2018 - 2028)
    • Infectious Diseases
    • Immunology
    • Oncology
    • Stem Cells
    • Neurobiology
    • Other Applications
  • Research Antibodies End-use Outlook (Revenue, USD Million, 2018 - 2028)
    • Academic & Research Institutes
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
  • Research Antibodies Regional Outlook (Revenue, USD Million, 2018 - 2028)
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Russia
    • Asia Pacific
      • China
      • Australia
      • India
      • Japan
      • Singapore
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • MEA
      • South Africa
      • Saudi Arabia
      • UAE

List of Key Players of Research Antibodies Market

  • Abcam Plc
  • Bio-rad Laboratories
  • Becton Dickinson & Company
  • Merck Millipore
  • Lonza Group
  • Thermo Fisher Scientific, Inc.
  • Cell Signalling Technology, Inc.
  • F. Hoffmann La Roche Ltd.
  • Agilent Technologies
  • Perkinelmer, Inc.

Check out more studies related to medical antibodies, conducted by Grand View Research:

  • Australia & New Zealand Research Antibodies Market–The Australia & New Zealand research antibodies market size was valued at USD 98.4 million in 2018 and is anticipated to grow at a CAGR of 8.4% during the forecast period.
  • Mammalian Polyclonal IgG Antibody Market–The global mammalian polyclonal IgG antibody market size was valued at USD 816.5 million in 2017 and is anticipated to witness a CAGR of 5.1% during the forecast period.
  • Antibody Production Market–The global antibody production market size was valued at USD 7.4 billion in 2016 and is projected to grow at 13.5% over the forecast period.

Browse through Grand View Research's coverage of the Global Biotechnology Industry

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: https://www.grandviewresearch.com 
Follow Us: LinkedIn | Twitter 

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

Modal title

Also from this source

Online Gambling Market to Hit $153.57 Billion by 2030 at CAGR 11.9% - Grand View Research, Inc.

Online Gambling Market to Hit $153.57 Billion by 2030 at CAGR 11.9% - Grand View Research, Inc.

The global online gambling market size is estimated to reach USD 153.57 billion by 2030, registering a CAGR of 11.9% from 2025 to 2030, according to...

Home Healthcare Market Poised to Reach $ 747.70 Billion by 2030 at CAGR 10.21% - Grand View Research, Inc.

Home Healthcare Market Poised to Reach $ 747.70 Billion by 2030 at CAGR 10.21% - Grand View Research, Inc.

The global home healthcare market size is expected to reach USD 747.70 billion by 2030, according to a report by Grand View Research, Inc., expanding ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.